Fig. 2: Epitope-specific anti-αSyn antibody titers in blood and CSF. | Nature Medicine

Fig. 2: Epitope-specific anti-αSyn antibody titers in blood and CSF.

From: Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

Fig. 2

UB-312 or placebo were administered at weeks 1, 5 and 13. a, Serum antibody titers increased predominantly after the third vaccination. The definition of seroconversion was met in 12/13 participants receiving all three doses (5/6 in the 300/100/100 μg group and 7/7 in the 300/300/300 μg group). Increases were more pronounced in the 300/100/100 μg treatment group compared with the 300/300/300 μg treatment group. Samples were analyzed in duplicate and data are expressed as logDF mean + s.d. b, CSF antibody titers were more pronounced in the 300/100/100 μg treatment group compared with the 300/300/300 μg cohort; levels were detectable in 4/6 and 1/7 participants, respectively. Samples were analyzed in duplicate and data are expressed as logDF mean + s.d. Numbers per group: placebo, n = 6; 300/100/100 μg, n = 7 up to week 13 and thereafter n = 6 until week 45; 300/300/300 μg, n = 7. logDF, log-dilution factor.

Back to article page